Evidence map›Paper›PMID 34024821›Full record

ArticleJournal of Alzheimer's disease : JAD2021

In Vivo Amyloid, Neurodegeneration, and Verbal Learning in Late Middle-Aged Hispanics.

Mouna Tahmi, Brady Rippon, Priya Palta, Greysi Sherwood, Gabriela Hernandez, Luisa Soto, Fernando Ceballos, Michelle Pardo, Krystal Laing, Kay Igwe and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Mouna TahmiDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Brady RipponDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Priya PaltaDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Greysi SherwoodDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Gabriela HernandezDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Luisa SotoDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Fernando CeballosDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Michelle PardoDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Krystal LaingDepartment of Neurology, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Kay IgweDepartment of Neurology, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Hengda HeDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Jeanne A TeresiResearch Division, Hebrew Home in Riverdale, Bronx, NY, USA.
Herman MorenoDepartment of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
Qolamreza RazlighiDepartment of Radiology, Weill Cornell Medicine, New York, NY, USA.
Adam M BrickmanDepartment of Neurology, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
José A LuchsingerDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Columbia University · USColumbia University Irving Medical Center · USHebrew Home · USSUNY Downstate Health Sciences University · USWeill Cornell Medicine · US

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Residing in the Community with Dementia at the End of Life: Understanding Hospice Use and Residential SettingP30AG028741 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBERT L SIU · 2010 to 2026
$21.9M
Diabetes Status and Brain Amyloid in Middle Aged HispanicsR01AG050440 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LUCHSINGER, JOSE ALEJANDRO · 2015 to 2025
$21.9M
Interdisciplinary Research to Understand the Interplay of Diabetes, Cerebrovascular disease and Alzheimers diseaseRF1AG051556 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, LUCHSINGER, JOSE ALEJANDRO · 2015 to 2019
$9.7M
Research Education CoreP30AG059303 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ADAM M BRICKMAN, Jennifer Jaie Manly · 2018 to 2026
$6.0M
Midcareer Award for Research in Dementia Risk Factors and PreventionK24AG045334 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jose Alejandro Luchsinger · 2016 to 2026
$1.5M
Physical Activity and Preservation of Cognitive FunctionR00AG052830 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALTA, PRIYA · 2019 to 2021
$1.1M
NCATS NIH HHS UL1 TR001873NIA NIH HHS K24 AG045334NIA NIH HHS P30 AG028741NIA NIH HHS P30 AG059303NIA NIH HHS R00 AG052830NIA NIH HHS R01 AG050440NIA NIH HHS RF1 AG051556
6 · The paper itself

Abstract

backgroundThe National Institute on Aging (NIA)/Alzheimer's Association (AA) 2018 framework conceptualizes Alzheimer's disease (AD) biologically. Evidence of brain amyloid by biomarkers defines AD pathologic change and the Alzheimer's continuum. The presence of tau or neurodegeneration in the absence of amyloid defines non-AD pathologic change.

objectiveTo examine the relation of in vivo amyloid and neurodegeneration with verbal learning, one of the cognitive abilities affected early in AD, in late middle age.

methodsThis was a cross-sectional study of amyloid and neurodegeneration biomarkers in a community-based cohort of 350 late-middle aged Hispanics without dementia (mean age: 64.15±3.34; 72.0%women). Amyloid (A) was measured as global standardized uptake value ratio (SUVR) with 18F-Florbetaben positron emission tomography (PET). Neurodegeneration (N) was ascertained as cortical thickness (CT) in AD signature areas using brain magnetic resonance imaging. We examined A/N continuously, categorically, by A/N profiles, and profile categories. The amyloid threshold for positivity was defined using the K means method. The CT threshold was defined as 2 standard deviations below the mean CT. Verbal learning was ascertained using total recall and delayed recall in the Buschke Selective Reminding test (SRT).

resultsHigher cortical thickness was associated with higher performance in SRT delayed recall. Amyloid SUVR was not related to SRT performance. The low CT category was associated with lower performance in SRT delayed recall, while Amyloid categories were not related to any SRT score. The non-AD pathologic change group (A-N+) performed worse in SRT delayed recall compared to the Normal A/N profile group (A-N-).

conclusionIn late middle-aged Hispanics without dementia, non-AD pathologic change, but not the Alzheimer's continuum, was related to verbal learning.

Indexed as

Verbal LearningAmyloidBiomarkersBrainCognitive DysfunctionCross-Sectional StudiesFemaleHispanic or LatinoHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyAmyloidBiomarkersamyloidA/T/(N)cognitionHispanicsneurodegenerationNIA-AA

Identifiers

PMID34024821
PMCPMC10323937
OpenAlexW3162067159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.